| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by investing activities | 46,202 | 28,919 |
| Proceeds from exercise of stock options | 8,745 | 7,061 |
| Net cash provided by financing activities | 8,745 | 7,061 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 6,906 | -4,934 |
| Cash and cash equivalents at beginning of period | 50,817 | - |
| Cash and cash equivalents at end of period | 57,723 | - |
Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp (ADPT)